Associated Papers
Frequent EPHA2 receptor mutations in cholangiocarcinoma disrupt receptor forward signaling supporting a tumor suppressor role.
Koutouan E et al.
Biochimica Et Biophysica Acta. Molecular Cell Research, 2026
Genetic spectrum of congenital cataract with optional ocular and multisystem abnormalities.
Zhang H et al.
Bmc Medical Genomics, 2025
Frequent EPHA2 receptor mutations in cholangiocarcinoma disrupt receptor forward signaling supporting a tumor suppressor role.
Koutouan E et al.
Biorxiv : the Preprint Server for Biology, 2025
Hallmarks of a genomically distinct subclass of head and neck cancer.
Muijlwijk T et al.
Nature Communications, 2024
39428388 (PubMed )
Supplement: 41467_2024_53390_MOESM4_ESM.xlsx › 3._List_of_all_somatic_variants
Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma.
Tessiri S et al.
Peerj, 2022
35070505 (PubMed )
Supplement: peerj-10-12750-s003.xlsx › Supplemental_Table1
Germ-line and somatic EPHA2 coding variants in lens aging and cataract.
Bennett TM et al.
Plos One, 2017
29267365 (PubMed )
Supplement: pone.0189881.s004.xlsx › S4a._Clear__1__all
Select a paper to view details